Baar, 4 February, 2021 - A new national campaign, launched in Switzerland by the patient platform “Leben mit Krebs” (Living with cancer), in partnership with AstraZeneca is urging cancer patients to contact their doctors and return to treatment following the disruption to care due to COVID-19. The public awareness campaign also calls on people to return to screening services and to also contact their doctors if they notice any possible cancer signs and symptoms
New Normal, Same Cancer is being launched in Switzerland by the patient platform “Leben mit Krebs” (Living with cancer), in partnership with AstraZeneca, to ensure people access the cancer care they need. The impact of COVID-19 means that patients with a diagnosis may have had reduced access to treatment; or their routine screening service may have been paused. Equally, people with possible cancer signs and symptoms may not be seeking medical help. Minimising the negative impact of the COVID-19 epidemic on patient outcomes is the driving force behind this important new campaign.
Cancer diagnoses dropped by approx. 40 % worldwide
While cancer has not stopped during the pandemic, in 2020, the pandemic resulted in a 40 % drop in patients being diagnosed with cancer worldwide.1 If the pandemic continues, this figure is likely to worsen.2 Research highlights that any interruption to the cancer care pathway can be detrimental to patient outcomes3,4, so it is critical that people return to seek cancer care.
New Normal, Same Cancer centres around three simple actions: Don’t wait. Contact your doctor. Get checked.
While the world is navigating a new normal, cancer has not stopped. Cancer continues to be one of the biggest global health challenges and there is an immediate need to support patients to return to healthcare environments.
he COVID-19 pandemic is impacting the lives of people around the world. However, cancer screening and treatment must not become less important. At AstraZeneca, we support the campaign and are committed to ensuring that cancer patients return to the care they urgently need.
Please find more information about the public awareness campaign in Switzerland at www.lebenmitkrebs.ch
AstraZeneca in Oncology
AstraZeneca has a deep-rooted heritage in oncology and offers a quickly growing portfolio of new medicines that has the potential to transform patients’ lives and the Company’s future. With seven new medicines launched between 2014 and 2020, and a broad pipeline of small molecules and biologics in development, the Company is committed to advance oncology as a key growth driver for AstraZeneca focused on lung, ovarian, breast and blood cancers.
By harnessing the power of four scientific platforms – Immuno-Oncology, Tumour Drivers and Resistance, DNA Damage Response and Antibody Drug Conjugates – and by championing the development of personalised combinations, AstraZeneca has the vision to redefine cancer treatment and, one day, eliminate cancer as a cause of death.
New Normal, Same Cancer background
AstraZeneca co-created the Global campaign in collaboration with global patient advocacy groups, including: ABC Global Alliance, Global Colon Cancer Association, International Kidney Cancer Coalition, Lung Cancer Europe, World Ovarian Cancer Coalition and World Pancreatic Cancer Coalition in response to widespread concerns among patient groups about the long-term impact that disruption to cancer care services will have on current and future cancer patients.
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.
AstraZeneca in Switzerland
AstraZeneca has 120 employees who are responsible for coordinating business operations in Switzerland. Our site in Baar is also the headquarters of the Europe & Canada Commercial Regional Team and the Europe & International Oncology Team, which employ a further 40 staff in Switzerland. Our primary therapeutic areas are Oncology, Cardiovascular, Renal and Metabolism, and Respiratory & Immunology. To meet our climate goals ahead of schedule, we are working tirelessly to further reduce CO2 emissions and waste. As part of our Ambition Zero Carbon strategy, we are transitioning to a carbon-free business operation by taking steps to reduce and ultimately eliminate greenhouse gas emissions. In 2020, AstraZeneca Switzerland was recognized by its employees for the third time as an outstanding employer, and was awarded the external “Great place to work®” certification.
Find out more: astrazeneca.ch
1. De Vincentiis L, et al. Cancer diagnostic rates during the 2020 ‘lockdown’, due to COVID-19 pandemic, compared with the 2018–2019: an audit study from cellular pathology. Journal of Clinical Pathology Published Online First: 19 June 2020. doi: https://jcp.bmj.com/content/early/2020/06/19/jclinpath-2020-206833
2. Richards, M., Anderson, M., Carter, P. et al. The impact of the COVID-19 pandemic on cancer care. Nat Cancer 1, 565–567 (2020). https://doi.org/10.1038/s43018-020-0074-y. Accessed January 2021.
3. Managing COVID-19 in the oncology clinic and avoiding the distraction effect. Online Source, Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7174827/: Accessed January 2020
4. Cancer patients and research during COVID-19 pandemic: A systematic review of current evidence: Online Source, Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7174983/#bib0090: Accessed January 2020
AstraZeneca Switzerland Media Department
Tel. +41 (0) 41 725 75 75; email@example.com
Dr. Angelika März, Corporate Affairs Lead
© 2021 AstraZeneca AG, Neuhofstrasse 34, 6340 Baar. All rights reserved.